<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>11(1)</volume><submitter>Cha JJ</submitter><funding>Dong-A ST CO., LTD.</funding><pubmed_abstract>Although dual antiplatelet therapy is essential for patients who undergo percutaneous coronary interventions, the risk of bleeding remains an unsolved problem, and there is limited information on the potential relationship between genetic variants and major bleeding. We analyzed the correlations between four major single nucleotide polymorphisms (CYP2C19, ABCB1, PON1, and P2Y12 G52T polymorphisms) and clinical outcomes in 4489 patients from a prospective multicenter registry. The primary endpoint was major bleeding, defined as a Bleeding Academic Research Consortium ≥ 3 bleeding event. The allelic frequencies of ABCB1, PON1, and both individual and combined CYP2C19 variants did not differ significantly between patient groups with and without major bleeding. However, the allelic frequency o</pubmed_abstract><journal>Scientific reports</journal><pagination>1790</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7815734</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Impact of genetic variants on major bleeding after percutaneous coronary intervention based on a prospective multicenter registry.</pubmed_title><pmcid>PMC7815734</pmcid><pubmed_authors>Park JH</pubmed_authors><pubmed_authors>Cho YH</pubmed_authors><pubmed_authors>Kang WC</pubmed_authors><pubmed_authors>Joo HJ</pubmed_authors><pubmed_authors>Kim BK</pubmed_authors><pubmed_authors>Yoon J</pubmed_authors><pubmed_authors>Kim W</pubmed_authors><pubmed_authors>Choi W</pubmed_authors><pubmed_authors>Kim YH</pubmed_authors><pubmed_authors>Lim YH</pubmed_authors><pubmed_authors>Lim DS</pubmed_authors><pubmed_authors>Ahn TH</pubmed_authors><pubmed_authors>Ahn SG</pubmed_authors><pubmed_authors>Shin W</pubmed_authors><pubmed_authors>Cha JJ</pubmed_authors><pubmed_authors>Gwon H</pubmed_authors><pubmed_authors>Hong SJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Impact of genetic variants on major bleeding after percutaneous coronary intervention based on a prospective multicenter registry.</name><description>Although dual antiplatelet therapy is essential for patients who undergo percutaneous coronary interventions, the risk of bleeding remains an unsolved problem, and there is limited information on the potential relationship between genetic variants and major bleeding. We analyzed the correlations between four major single nucleotide polymorphisms (CYP2C19, ABCB1, PON1, and P2Y12 G52T polymorphisms) and clinical outcomes in 4489 patients from a prospective multicenter registry. The primary endpoint was major bleeding, defined as a Bleeding Academic Research Consortium ≥ 3 bleeding event. The allelic frequencies of ABCB1, PON1, and both individual and combined CYP2C19 variants did not differ significantly between patient groups with and without major bleeding. However, the allelic frequency o</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Jan</publication><modification>2026-05-02T21:41:46.088Z</modification><creation>2021-02-21T01:57:35Z</creation></dates><accession>S-EPMC7815734</accession><cross_references><pubmed>33469058</pubmed><doi>10.1038/s41598-020-80319-9</doi></cross_references></HashMap>